Summary
Presently, less than one drugable compound on ten entering clinical trials effectively reaches the market. This excessive drug attrition rate is mainly due to insufficient preclinical studies of new chemical entities. Drug Design and Development (DDD) might be derisked by the...
More information & hyperlinks
| Web resources: | http://www.isotopics-project.eu/ |
Search
Associated projects
Organisations
- Not specified